Search Results for: 19

ROCKVILLE, Md., Dec. 11, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today the pricing of an underwritten public offering of 11,500,000 shares of common stock at a public offering price of $1.00 per share. The Company […]

ROCKVILLE, Md., Dec. 11, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today the pricing of an underwritten public offering of 11,500,000 shares of common stock at a public offering price of $1.00 per share. The Company

ROCKVILLE, Md., Dec. 11, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today that it intends to offer for sale shares of its common stock in an underwritten public offering. The Company intends to use the net

— Webcast to be held Monday, December 9th at 9:00 a.m. EST — ROCKVILLE, Md., Dec. 7, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious diseases and other diseases, announced today that it entered into worldwide license and option agreements with

ROCKVILLE, Md., Dec. 2, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases,  announced today that Jeffrey Riley, CEO, will present at the LD MICRO VI: Main Event Conference at 9:30 a.m. (PT) on Wednesday, December 4, 2013. The conference will be

— Company to Present at the 2013 Therapeutic Area Partnerships Conference — ROCKVILLE, Md., Nov. 14, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, today announced that SYN-004, Synthetic Biologics’ product candidate for the prevention of C. difficile infections, was selected

— Conference Call Today, November 14, at 10 a.m. Eastern Time — ROCKVILLE, Md., Nov. 14, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, today reported financial results for the three and nine months ended September 30, 2013 and provided an

— Company Focused on Novel Anti-Infectives for the Prevention and Treatment of Serious Infectious Diseases — — Conference Call Scheduled for Thursday, November 14, 2013, at 10:00 am EST — ROCKVILLE, Md., Nov. 7, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious

Company’s Proprietary Oral Beta-Lactamase Enzyme Successful Evaluation Conducted by FUJIFILM Diosynth Biotechnologies UK Limited ROCKVILLE, Md., Oct. 15, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today the successful completion of the protein expression evaluation with regard to the

ROCKVILLE, Md., Sept. 20, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, has issued a response to the recent report issued by the Centers for Disease Control and Prevention (CDC) earlier this week that detailed the growing threat of antibiotic-resistant “super